Rapamycin (sirolimus)

Sirolimus, also known as rapamycin, is an immunosuppressant drug used to prevent rejection in organ transplantation and has recently been prescribed for patients with certain chronic inflammatory diseases such as Alzheimers disease.1)

My assessment is that any of our members who take Rapamycin run the risk of their IP becoming totally unstable, and becoming very ill indeed….

Please stay away from mTOR inhibitors like Rapamycin. Even at quite low doses they affect the human body in far more profound ways than the more common corticosteroidsA first-line treatment for a number of diseases. Corticosteroids work by slowing the innate immune response. This provides some patients with temporary symptom palliation but exacerbates the disease over the long-term by allowing chronic pathogens to proliferate., which have also proven to be dangerous, by leading to physical dependence and IP (immunopathologyA temporary increase in disease symptoms experienced by Marshall Protocol patients that results from the release of cytokines and endotoxins as disease-causing bacteria are killed.) instability. I fear the emphasis on Rapamycin and mTOR in the media might tempt MP members to experiment, members whose bodies are still too ill to withstand the cardiovascular effects of this drug.

Trevor Marshall, PhD MarshallProtocol.com

===== Notes and comments =====

===== References =====

Ma T, Hoeffer CA, Capetillo-Zarate E, Yu F, Wong H, Lin MT, Tampellini D, Klann E, Blitzer RD, Gouras GK. Dysregulation of the mTOR pathway mediates impairment of synaptic plasticity in a mouse model of Alzheimer's disease. PLoS One. 2010 Sep 20;5(9):e12845. doi: 10.1371/journal.pone.0012845.
[PMID: 20862226] [PMCID: 2942840] [DOI: 10.1371/journal.pone.0012845]
home/othertreatments/rapamycin.txt · Last modified: 09.14.2022 by
© 2015, Autoimmunity Research Foundation. All Rights Reserved.